Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, p.6199206, 2009. ,
DOI : 10.1200/JCO.2009.23.4799
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035/pdf
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, p.35865, 2012. ,
DOI : 10.1016/S0140-6736(12)60868-X
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, p.250716, 2011. ,
DOI : 10.1056/NEJMoa1103782
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, p.3039, 2015. ,
DOI : 10.1056/NEJMoa1412690
-Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, p.186776, 2014. ,
DOI : 10.1056/NEJMoa1408868
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, p.71123, 2010. ,
DOI : 10.1056/NEJMoa1003466
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/pdf
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, p.251726, 2011. ,
DOI : 10.1056/NEJMoa1104621
Mutation, New England Journal of Medicine, vol.372, issue.4, p.32030, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00872683
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, p.37584, 2015. ,
DOI : 10.1016/S1470-2045(15)70076-8
« Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, p.90818, 2015. ,
DOI : 10.1016/s1470-2045(15)00083-2
Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, p.252132, 2015. ,
DOI : 10.1056/NEJMoa1503093
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, pp.1889-94, 2015. ,
DOI : 10.1200/JCO.2014.56.2736
Donn??es actualis??es d???efficacit?? et de tol??rance de l???ipilimumab en ????vie r??elle???? via la cohorte Melbase, Annales de Dermatologie et de V??n??r??ologie, vol.143, issue.12, 1989. ,
DOI : 10.1016/j.annder.2016.09.243
Donn??es d???efficacit?? en vie r??elle des inhibiteurs de PD1??dans le m??lanome m??tastatique, Données d'efficacité en vie réelle des inhibiteurs de PD1 dans le mélanome métastatique, p.178, 2016. ,
DOI : 10.1016/j.annder.2016.09.208
Efficacit?? et tol??rance ????en vie r??elle???? des immunoth??rapies anti-PD1??chez les patients atteints de m??lanome stade III inop??rable ou IV au sein de la cohorte nationale MelBase, Annales de Dermatologie et de V??n??r??ologie, vol.142, issue.12, 2015. ,
DOI : 10.1016/j.annder.2015.10.088
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, p.22847, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies, Cancer, vol.33, issue.15 suppl, p.33443353, 2016. ,
DOI : 10.1016/j.jaut.2015.08.020
??valuation de la r??ponse des m??lanomes muqueux et choro??diens ?? l???immunoth??rapie par anti-CTLA4??et/ou anti-PD1, Évaluation de la réponse des mélanomes muqueux et choroïdiens à l'immunothérapie par anti-CTLA4 et/ou anti-PD1 », p.196, 2016. ,
DOI : 10.1016/j.annder.2016.09.239
Wild-Type Advanced Melanoma, JAMA Oncology, vol.1, issue.4, p.43340, 2015. ,
DOI : 10.1001/jamaoncol.2015.1184
Determinants of Outcome in Melanoma Patients With Cerebral Metastases, Journal of Clinical Oncology, vol.22, issue.7, p.12931300, 2004. ,
DOI : 10.1200/JCO.2004.08.140
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Oncotarget, vol.7, p.7740415, 2016. ,
DOI : 10.18632/oncotarget.12677
URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=12677&path%5B%5D=40163
« Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol, vol.27, p.73238, 2016. ,
DOI : 10.1093/annonc/mdx059
Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy, International Immunopharmacology, vol.40, p.46673, 2016. ,
DOI : 10.1016/j.intimp.2016.09.030
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.35, issue.7, p.78592, 2017. ,
DOI : 10.1200/JCO.2015.66.1389
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis, Journal of Clinical Oncology, vol.33, issue.7, p.77381, 2015. ,
DOI : 10.1200/JCO.2014.57.4756
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, New England Journal of Medicine, vol.366, issue.10, p.92531, 2012. ,
DOI : 10.1056/NEJMoa1112824
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, p.86270, 2004. ,
DOI : 10.1016/j.ijrobp.2003.09.012
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade, Cancer Research, vol.74, issue.19, p.545868, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-1258
URL : http://cancerres.aacrjournals.org/content/canres/74/19/5458.full.pdf
Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy, JAMA Dermatology, vol.153, issue.10, 2017. ,
DOI : 10.1001/jamadermatol.2017.2222
Immunoth??rapie anti-PD-1??et radioth??rapie concomitante dans le m??lanome m??tastatique??: donn??es cliniques pr??liminaires d???efficacit?? et de tol??rance, Annales de Dermatologie et de V??n??r??ologie, vol.143, issue.12, p.199, 2016. ,
DOI : 10.1016/j.annder.2016.09.244
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma, European Journal of Cancer, vol.75, p.4755, 2017. ,
DOI : 10.1016/j.ejca.2017.01.009
Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features, European Journal of Cancer, vol.75, p.24344, 2017. ,
DOI : 10.1016/j.ejca.2016.12.040
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Annals of Oncology, vol.27, issue.4, p.55974, 2016. ,
DOI : 10.1093/annonc/mdv623
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Annals of Oncology, vol.28, p.36876, 2017. ,
DOI : 10.1093/annonc/mdw443